cas 871254-61-4|| where to buy 2,4-dichloropyrimidine-5-carbaldehyde

Nom du produit:2,4-dichloropyrimidine-5-carbaldehyde

IUPAC Name:2,4-dichloropyrimidine-5-carbaldehyde

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM108816-5g	in stock	ȀǕň

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 871254-61-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:871254-61-4; Formule moléculaire:C5H2Cl2N2O; Point de fusion:-; Code SMILES:O=CC1=CN=C(Cl)N=C1Cl; Densité:

: Numéro de catalogue:CM108816; Poids moléculaire:176.98; Point d'ébullition:; N° Mdl:MFCD11112096; Stockage:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Ribociclib; FDA has approved Novartis Kisqali(ribociclib) to reduce risk of recurrence in people with hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-) early breast cancer (EBC).
Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Beyond today’s FDA approval of Kisqali for EBC patients in the US, regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China.